The key efficacy endpoint was transform from baseline MADRS score. This short-expression study located that, compared to intranasal placebo plus oral antidepressant, intranasal esketamine in conjunction with an oral antidepressant appreciably enhanced depressive signs or symptoms after four months by a imply difference of four points around the MADRS. The https://borisb566fui4.blogtov.com/profile